Jan H Cornel
Overview
Explore the profile of Jan H Cornel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
8377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Bijl M, van der Veen J, Fiolet A, Boersma E, Cornel J, Eikelboom J, et al.
J Am Heart Assoc
. 2025 Feb;
14(5):e040412.
PMID: 39996509
No abstract available.
2.
Jolly S, dEntremont M, Lee S, Mian R, Tyrwhitt J, Kedev S, et al.
N Engl J Med
. 2024 Nov;
392(7):633-642.
PMID: 39555823
Background: Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. Methods: In this multicenter trial with a 2-by-2 factorial...
3.
Jolly S, dEntremont M, Pitt B, Lee S, Mian R, Tyrwhitt J, et al.
N Engl J Med
. 2024 Nov;
392(7):643-652.
PMID: 39555814
Background: Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial after myocardial infarction is...
4.
Mohammadnia N, van Broekhoven A, Bax W, Eikelboom J, Mosterd A, Fiolet A, et al.
Eur J Prev Cardiol
. 2024 Oct;
PMID: 39478683
Aims: Inflammatory lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs) on lipoproteins convey residual cardiovascular disease risk. The LoDoCo2 (low-dose colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events...
5.
Fiolet A, Poorthuis M, Opstal T, Amarenco P, Boczar K, Buysschaert I, et al.
EClinicalMedicine
. 2024 Oct;
76:102835.
PMID: 39431112
Background: Guidelines recommend low-dose colchicine for secondary prevention in cardiovascular disease, but uncertainty remains concerning its efficacy for stroke, efficacy in key subgroups and about uncommon but serious safety outcomes....
6.
Budgeon C, Nidorf S, Mosterd A, Fiolet A, Eikelboom J, OHalloran S, et al.
Am Heart J
. 2024 Sep;
278:186-194.
PMID: 39313104
Background: The Low Dose Colchicine 2 (LoDoCo2) trial randomized 5,522 patients with chronic coronary disease to colchicine 0.5mg daily or placebo in a 1:1 ratio and demonstrated the cardiovascular benefits...
7.
Gibson C, Chi G, Duffy D, Bahit M, White H, Korjian S, et al.
J Am Coll Cardiol
. 2024 Sep;
84(22):2185-2192.
PMID: 39230545
Background: Following an acute myocardial infarction (AMI), patients remain at risk for subsequent cardiovascular (CV) events. In the AEGIS-II trial, CSL112, a human apolipoprotein A-I derived from plasma that enhances...
8.
Gibson C, Duffy D, Bahit M, Chi G, White H, Korjian S, et al.
Eur Heart J
. 2024 Sep;
45(47):5023-5038.
PMID: 39221651
Background And Aims: In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary...
9.
Jain S, Mahaffey K, Pieper K, Shimizu W, Potpara T, Ruff C, et al.
Am Heart J
. 2024 Aug;
277():145-158.
PMID: 39214801
Background: Direct oral anticoagulants are the standard of care for stroke prevention in eligible patients with atrial fibrillation and atrial flutter; however, bleeding remains a significant concern, limiting their use....
10.
Tercan H, van Broekhoven A, Bahrar H, Opstal T, Cossins B, Rother N, et al.
Clin Pharmacol Ther
. 2024 Aug;
116(5):1325-1333.
PMID: 39115262
Recent landmark trials showed that colchicine provides a substantial benefit in reducing major cardiovascular events in patients with coronary artery disease. Yet, its exact mechanism of action is still poorly...